Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation

Döhner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129 , 424–447 (2017). Article Google Scholar Schmid, C., Schleuning, M., Ledderose, G., Tischer, J. & Kolb, H. J. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol. 23 , 5675–5687 (2005). Article Google Scholar Grimm, J. et al. Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation. Blood Adv. 4 , 3864–3874 (2020). Article CAS Google Scholar Thol, F. et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood 132 , 1703–1713 (2018). Article CAS Google Scholar Bill, M. et al. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients. Ann. Hematol 97 , 1757–1765 (2018). Article CAS Google Scholar Jentzsch, M. et al. Prognostic impact of blood MN1 copy numbers before allogeneic stem cell transplantation in patients with acute myeloid leukemia. HemaSphere 3 , e167 (2019). Article Google Scholar Jentzsch, M. et al. High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients. Oncotarget 8 , 87944–87954 (2017). Article Google Scholar Ivey, A. et al. Assessment of minimal residual disease in standard-risk AML. N. Engl. J. Med. 374 , 422–433 (2016). Article CAS Google Scholar Schuurhuis, G. J. et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131 , 1275–1291 (2018). Article CAS Google Scholar Araki, D. et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J. Clin. Oncol. 34 , 329–336 (2016). Article Google Scholar Giralt, S. et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 , 4531–4536 (1997). Article CAS Google Scholar Hourigan, C. S. et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J. Clin. Oncol. 38 , 1273–1283 (2020). Article CAS Google Scholar Dillon, R. et al. Molecular MRD status and outcome after transplantation in NPM1 -mutated AML. Blood 135 , 680–688 (2020). Article CAS Google Scholar Lu, Y. et al. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status. Ann. Hematol. 99 , 2911–2925 (2020). Article Google Scholar Chang, Y. J. et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J. Hematol. Oncol. 10 , 1–13 (2017). Article Google Scholar Download references